Intervention Protocol

You have free access to this content

Behavioural interventions for reducing weight gain in schizophrenia

  1. Guy Faulkner1,*,
  2. Markus J Duncan1,
  3. Margaret Hahn2,
  4. Gary Remington3,
  5. Tony Cohn4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 15 OCT 2013

DOI: 10.1002/14651858.CD010781

How to Cite

Faulkner G, Duncan MJ, Hahn M, Remington G, Cohn T. Behavioural interventions for reducing weight gain in schizophrenia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010781. DOI: 10.1002/14651858.CD010781.

Author Information

  1. 1

    University of Toronto, Faculty of Kinesiology and Physical Education, Toronto, Ontario, Canada

  2. 2

    Center for Addiction and Mental Health, Complex Mental Illness, Toronto, Canada

  3. 3

    University of Toronto, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

  4. 4

    Centre for Addiction and Mental Health, Schizophrenia Program and MAPS, Toronto, Ontario, Canada

*Guy Faulkner, Faculty of Kinesiology and Physical Education, University of Toronto, 55 Harbord St, Toronto, Ontario, On M5S 2W6, Canada.

Publication History

  1. Publication Status: New
  2. Published Online: 15 OCT 2013



Additional references

  1. Additional references
  2. References to other published versions of this review
ADA/APA 2004
  • America Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601.
Allison 1999
  • Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 1999;156(11):1686-9.
Allison 2003
Altman 1996
Ananth 2004
  • Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S. Atypical antipsychotic induced weight gain: pathophysiology and management. Annals of Clinical Psychiatry 2004;16:75-85.
Baptista 2002
  • Baptista, T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration : Mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35:205-19.
Birt 2003
  • Birt 2003. Management of weight gain associated with antipsychotics. Annals of Clinical Psychiatry 2003;15:49-58.
Bland 1997
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
Brown 1999
Caemmerer 2012
  • Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomised controlled trials. Schizophrenia Research 2012;140:159-68.
Casey 2004
  • Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, et al. Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. Journal of Clinical Psychiatry 2004;65(Suppl 7):4-18.
Catapana 2004
Cohn 2004
  • Cohn T, Prud'homme D, Steiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome . Canadian Journal of Psychiatry 2004;49:753-60.
Coodin 2001
Daumit 2003
  • Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE. Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. Journal of Nervous and Mental Disease 2003;191:799-805.
Daumit 2005
  • Daumit GL, Goldberg RW, Anthony C, Dickerson F, Brown CH, Kreyenbuhl J, et al. Physical activity patterns in adults with severe mental illness. Journal of Nervous and Mental Disease 2005;193:641-6.
De Hert 2011
  • De Hert M,  Detraux J,  van Winkel R,  Yu W,  Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology 2011;8(2):114-26.
De Nayer 2005
  • De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J on behalf of the Consensus Group. Belgian consensus on metabolic problems associated with atypical antipsychotics. International Journal of Psychiatry in Clinical Practice 2005;9:130-7.
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Dipasquale 2013
  • Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: A systematic review. Journal of Psychiatric Research 2013;47:197-207.
Divine 1992
DoH 2004
  • Department of Health. At least five a week. A report from the Chief Medical Officer. At least five a week. A report from the Chief Medical Officer. London: HMSO, 2004.
Donner 2002
Egger 1997
Elbourne 2002
  • Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Faulkner 1999
  • Faulkner G, Biddle S. Exercise and schizophrenia: A review. Journal of Mental Health 1999;8:441-7.
Faulkner 2003
Faulkner 2007a
  • Faulkner G,  Cohn T,  Remington G,  Irving H. Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophrenia Research 2007;90(1-3):174-8.
Fontaine 2001
  • Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Research 2001;101:277-88.
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
Goff 2005
  • Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah NA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.. Schizophrenia Research 2005;80:45-53.
Gorczynski 2010
Green 2000
Gulliford 1999
  • Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
Gurpegui 2012
  • Gurpegui M, Martínez-Ortega JM, Gutiérrez-Rojas L, Rivero J, Rojas C, Jurado D. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2012;37(1):169-75.
Hahn (in progress)
  • Hahn M, Remington G, Duncan M, Faulkner G. Pharmacological interventions for reducing weight gain in schizophrenia. Cochrane Database of Systematic Reviews In progress.
Hamoui 2004
Henderson 2005
  • Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study. Journal of Clinical Psychiatry 2005;66:1116-21.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from
Homel 2002
Hutton 2009
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Kurzthaler 2001
  • Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. Journal of Clinical Psychiatry 2001;62(Supple 7):32-7.
Le Fevre 2001
  • Le Fevre PD. Improving the physical health of patients with schizophrenia: Therapeutic nihilism or realism?. Scottish Medical Journal 2001;46:11-31.
Leucht 2007
  • Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
Loh 2006
  • Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Annals of Clinical Psychiatry 2006;18:23-31.
Maayan 2010
  • Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Biological Psychiatry 2010;35:1520-30.
Mackin 2005
  • Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study. Diabetologia 2005;48:215-21.
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
Osborn 2001
Peeters 2003
  • Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L, NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annual of Internal Medicine 2003;138:24-32.
Reynolds 2010
Saari 2005
  • Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 birth cohort study. Journal of Clinical Psychiatry 2005;66:559-63.
Saha 2007
  • Saha S, Chant D, McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Archives of General Psychiatry 2007;64:1123-31.
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
Shaw 2005
Silverstone 1988
Snow 2005
  • Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine 2005;142:11-9.
Strassnig 2003a
Strassnig 2003b
Susce 2005
  • Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: A cross-sectional survey. Journal of Clinical Psychiatry 2005;66:167-73.
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
Vancampfort 2011
Wei 1999
  • Wei M, Kampert JB, Barlow CE, Nichaman MZ, Gibbons LW, Paffenbarger RS Jr, et al. Relationship between low cardiorespiratory fitness and mortality in normal weight, overweight and obese men. JAMA 1999;282:1547-53.
Weiden 2004
Werneke 2002
  • Werneke U, Taylor D, Sanders TAB. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. International Clinical Psychopharmacology 2002;17:145-60.
Werneke 2003
Wilding 1997
Wirshing 2004
  • Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. Journal of Clinical Psychiatry 2004;65(Suppl 18):13-26.
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.

References to other published versions of this review

  1. Additional references
  2. References to other published versions of this review
Faulkner 2007b